Lilly schedules Byetta conference; Antipsychotic use in elderly still rising;

> In the wake of last week's FDA advisory on pancreatitis in Byetta patients, Eli Lilly has scheduled a conference call for investors this afternoon at 5 p.m., with its VP of global patient safety, SVP of R&D, and Amylin's CEO and president on the line. Report

> Safety warnings slowed the use of antipsychotic drugs in seniors with dementia, but overall use in the elderly has increased, suggesting that warnings may not be enough to protect patients, Canadian researchers say. Report

> In the latest update on FDA's regulatory push into China, HHS secretary Michael Leavitt says as many as 15 agency inspectors will be assigned to Beijing, Shanghai, and Guangzhou in October. Report

> Biovail got Canadian regulators' nod for an expanded indication for its pain med Ralivia; the drug is now approved for treatment of moderately severe pain as well as moderate pain. Biovail release

> Generex Biotechnology has inked a licensing and distribution deal with Dong-Sung Pharm to sell its Generex Oral-lyn, the company's proprietary oral insulin spray product, in South Korea. Generex release

> Distributing antiretroviral drugs in Malawi has dramatically slashed the number of AIDS-related deaths, the World Health Organization says. Report

> Despite a lack of office space or even a complete research team, newcomer ProteoStasis Therapeutics has secured a whopping $45 million in Series A financing. VC report

> Crain's Detroit Business is reporting that NanoBio--a 2008 Fierce 15 company--is close to announcing an $11 million round of funding. It will likely be the last batch funding before the Ann Arbor-based company goes on the hunt for a Big Pharma partner. NanoBio report

> Durham, NC-based Adherex is warning investors that it will have to close operations unless it can secure additional funding. Report

> In a blow to NicOx, Pfizer decided not to launch a Phase III program for PF-03187207 in Asia. Report

> A single injection of the hormone leptin proved sufficient to heal terminally ill mice sickened by type 1 diabetes. Report

> Boston-based Genzyme has joined a research consortium targeted at finding new ways to fight malaria. Report

And Finally... By manipulating levels of the protein BMP-7, Harvard Medical School researchers were able to generate a larger store of "brown" fat cells that burn calories--a pathway that could be used to pursue new therapies to fight obesity and a range of metabolic diseases. Article